Trevicta (previously Paliperidone Janssen) (paliperidone)
- Region
- 🇪🇺 EU
- Active substance
- paliperidone
- Company
- Janssen-Cilag International NV
- Status
- Authorised
- Therapeutic area
- Schizophrenia
- EU approval
- Fri 05 Dec 2014
- Application
- EMEA/H/C/004066
- ATC
- N05AX13
- Official record
- www.ema.europa.eu
Indication
Trevicta, a 3 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly paliperidone palmitate injectable product.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Byannli (previously Paliperidone Janssen-Cilag International) Authorised ·
- 🇪🇺 Xeplion Authorised · Janssen-Cilag International
- 🇪🇺 Invega Authorised · Janssen-Cilag International NV
- 🇪🇺 Niapelf Authorised · Neuraxpharm Pharmaceuticals S.L.
Follow Trevicta (previously Paliperidone Janssen)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.